Obermatt
See Similar Stocks →

Coloplast

CPH:COLO B · DK0060448595
Health Care Equipment & SuppliesX-Large

360

39
EV / EBIT49
Price / Owner Earnings7
Owner Earnings Yield41
Dividend Yield93
Price/Sales39
EV / Gross Profit43
Price/Book11
Return on Capital93
Cash Return on Capital50
Return on Equity82
EBIT Margin88
Gross Profitability72
Cash Conversion85
Accruals75
Owner Earnings Margin48
Sales growth39
Profit Growth69
Long-Term EPS Growth58
Owner Earnings Growth15
Reinvestment50
Price momentum5
Debt load5
Refinancing72
Debt Payback10
Liquidity66
Analyst ratings1
Opinion Changes72
Price Target Upside62
Market mood75
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Coloplast clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryDenmark
IndustryHealth Care Equipment & Supplies
SizeX-Large
TypePublic Company
ExchangeCPSE
Employees7,474
Websitecoloplast.dk
ISINDK0060448595
Last UpdateApr 2, 2026
Indices
OMX C20 (Denmark)Renewable Energy Users
Themes
Women's HealthChronic DiseasesUrologySurgeryRespiratoryBiomedical EngineeringHealth CareManufacturingMedical Device

Description

Coloplast A/S is a global healthcare company that develops and markets products and services related to ostomy care, continence care, wound and skin care, and interventional urology. The company strives to deliver innovative solutions that empower cu…

Analysis

Quality compounder

Coloplast A/S earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 55.5×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 20% a year, against analyst forecasts of 10%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is stretched. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
22
2023202420252026

All-time high

35

Dec 2025

All-time low

1

Mar 2026

Average rank

12

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
39
7
6
7
Price/Earnings
30
19
17
8
Price/Book
11
3
1
3
Dividend Yield
93
90
76
80
Value (overall)
44
32
19
19

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Coloplast with its peers
EDAP TMS
NMQ:EDAP
11
CountryFrance
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Convatec Group
LSE:CTEC
65
CountryUK
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
IVF Hartmann
SWX:VBSN
68
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Steris
NYQ:STE
63
CountryIreland
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
medmix
SWX:MEDX
54
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →